Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Facing death: the last drawings of a woman with breast cancer at the end of life.

NPJ breast cancer·2026
Same author

Postbiotics in Dairy: A Comprehensive Review of Applications and Health Impacts.

Current nutrition reports·2026
Same author

Ovarian Metastasis from EBV-Associated Undifferentiated Nasopharyngeal Carcinoma: An Exceptionally Rare Occurrence.

Anticancer research·2026
Same author

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.

Current treatment options in oncology·2026
Same author

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Same author

Key Methodological Considerations in the Interpretation of the CONKO-007 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Mar 24, 2026

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

1.1K

Crizotinib-induced toxicity in an experimental rat model.

Ozge Gumusay1, Guldal Esendagli-Yilmaz2, Aytug Uner3

  • 1Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Gaziosmanpasa University, 60250, Tokat, Turkey. ozgebostankolu@hotmail.com.

Wiener Klinische Wochenschrift
|March 16, 2016
PubMed
Summary

Crizotinib, an ALK inhibitor, caused significant lung and liver toxicity in rats. Histopathological findings included intraalveolar hemorrhage, portal inflammation, and necrosis, indicating visceral organ damage.

Keywords:
CrizotinibPulmonary intraalveolar hemorrhageRatToxicity

More Related Videos

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.3K
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
09:27

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

12.7K

Related Experiment Videos

Last Updated: Mar 24, 2026

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

1.1K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.3K
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
09:27

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

12.7K

Area of Science:

  • Pharmacology
  • Toxicology
  • Histopathology

Background:

  • Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor used in cancer therapy.
  • Understanding its potential toxic effects on visceral organs is crucial for patient safety.

Purpose of the Study:

  • To investigate the histopathological effects of crizotinib on visceral organs in an experimental rat model.
  • To characterize the toxicity profile of crizotinib in vivo.

Main Methods:

  • Wistar albino rats were administered crizotinib (10 mg/kg) orally for 28 or 42 days.
  • Control rats received distilled water.
  • Blood and tissue samples were collected for histopathological analysis.

Main Results:

  • Crizotinib induced abnormal histology primarily in the lungs and liver.
  • Lung findings included intraalveolar hemorrhage.
  • Liver exhibited portal inflammation and necrosis; pancreas showed focal pancreatitis.

Conclusions:

  • This study provides the first histopathological evaluation of crizotinib toxicity in a rat model.
  • The findings highlight potential risks to the lungs, liver, and pancreas associated with crizotinib treatment.